Debt Financing
Rockwell Medical borrows $125 million from Vantive to buy its dialysis business
Vantive is financing its own sale with $100 million of secured term loans and a $25 million convertible note. Rockwell, which had $24.8 million of cash and investments in June, takes on rising interest margins and a dilution vote.

Rockwell Medical (Nasdaq: RMTI) agreed on November 2 to buy the in-center hemodialysis business of Vantive Limited for a base price of $125 million, and the seller is lending it all of the money. President and Chief Executive Officer Mark Strobeck, Ph.D., called the deal "a transformative step" in the company's evolution. Its shareholders would carry $100 million of secured seller term loans with margins that rise every year, a $25 million convertible note, up to $45 million of earnout payments, and a wait until mid-2027 for closing. In Rockwell's favor, it can repay the loans at par at any time, and the loan agreement has no financial maintenance covenants. Rockwell release · November 3 filing
What Rockwell is buying
Rockwell would take all the equity of Gambro Dasco S.p.A., which runs the manufacturing campus in Medolla, Italy, and of Vantive Korea Incorporated and the business's assets elsewhere, across 35 jurisdictions. The products are concentrates, hemodialysis machines including the AK-98, water treatment systems, bloodlines and technical services, with an installed base the presentation puts at ~100,000 machines. Rockwell estimates the combined company could bring in annual revenue between $400 million and $450 million, assuming successful integration. Its own net sales were $35.1 million in the first six months of 2026. The filing warns that the acquired business is several times the size of Rockwell's existing business and operates principally outside the United States. November 3 filing · Investor presentation · August 13 quarterly filing
How the seller financing works
Vantive Finance I Limited is the lender on two $50 million term loans, guaranteed by Rockwell Transportation, Inc. and secured by substantially all of the company's assets. Both pay Term SOFR, with a 2.50% floor, plus a margin that climbs 0.75% on each anniversary of closing: Tranche A runs from 5.50% to 9.25% and Tranche B from 7.00% to 10.75%. Tranche A interest may be paid in kind at an extra 0.50%; Tranche B is cash pay. Both mature on the sixth anniversary of closing. Proceeds of new share sales, other than permitted issuances, go first to prepaying Tranche B, and a Nasdaq delisting is an event of default. The filing names no administrative agent or arranger; Vantive Finance I Limited is the only lender. November 3 filing
The $25 million convertible note goes to Vantive Manufacturing Limited in a Section 4(a)(2) private placement reported under Item 3.02. It is unsecured, subordinated to the term loans, accrues 3.0% interest in kind and converts at $14.94 a share, which the filing says is 200% of a reference price of $7.47 fixed in the note; the release calls it a 100% premium to the 15-day volume-weighted average price. Without stockholder approval under Nasdaq Listing Rule 5635, conversions stop at 19.99% of the shares outstanding before signing. By our arithmetic, the full principal would convert into more than 40% of the 4,030,465 shares outstanding on August 10, about twice the cap. Rockwell has agreed to put the question to every annual meeting after closing until it passes. The earnout pays Vantive 30% of pro forma EBITDA above $10 million a year, up to $25 million, plus $10 million each if revenue tops $480 million and $500 million. November 3 filing · August 13 quarterly filing
Rockwell's own balance sheet
The quarterly report signed by Strobeck and Senior Vice President and Chief Financial Officer Jesse Neri shows about $24.8 million of cash, cash equivalents and investments at June 30, 2026. Operations generated $1.9 million of cash in the first half, though the company still lost $0.74 per share. Its term loans with Innovatus Life Sciences Lending Fund I, L.P., continued at $8.0 million in 2024 and due January 1, 2029, will be repaid at closing. A one-for-ten reverse split on July 1 cured a Nasdaq bid price notice, and compliance was confirmed on July 16. August 13 quarterly filing · November 3 filing
DaVita, holder of the Series X Convertible Preferred Stock, can limit new debt to narrow categories, such as a working capital line of up to $5.0 million, unless it consents. The filing lists that consent as a risk and says it is not a condition to closing. Rockwell has also withdrawn its 2026 guidance and says its registered offerings are limited while the deal is pending. For most breaches of Vantive's representations, its only recourse is an insurance policy it has not yet bound. November 3 filing · Rockwell release · August 13 quarterly filing
Advisers and the road to closing
Aquilo Partners, L.P. is exclusive financial advisor to Rockwell and Gibson Dunn & Crutcher LLP is its legal counsel. Perella Weinberg Partners LP and Barclays advise Vantive, with Kirkland & Ellis LLP as counsel. Closing requires merger control and foreign investment clearances, including Italy's golden power review, Vantive's internal reorganization and separation from Baxter's information technology systems, and audited 2025 and 2026 statements of the business. Afterward, Rockwell will depend on Vantive for transition services for up to 18 months and for products from Vantive plants in Italy, Mexico, Tunisia, Germany and France. Either side may terminate if the deal has not closed by November 1, 2027, extendable to April 29, 2028, and neither pays a termination fee. November 3 filing · Rockwell release
Investor Chat
Loading posts…
aibio